3.1 Lower Urinary Tract Pharmacotherapy

3.1 Lower Urinary Tract Pharmacotherapy

Pharmacotherapy represents the initial therapeutic modality for most men and women presenting with lower urinary tract symptoms (LUTS). A mastery of receptor distribution, intracellular signalling cascades, pharmacokinetic parameters, and drug interactions is essential for both the European Board of Urology examinations and safe clinical practice.

---

1. Alpha-1 Adrenergic Receptor Antagonists

Alpha-1 adrenergic receptor antagonists (alpha-blockers) are first-line agents for male moderate-to-severe LUTS secondary to benign prostatic enlargement (BPE). They reduce smooth muscle tone in the prostate stroma, capsule, and bladder neck without altering prostate volume or halting disease progression.

Subtype Selectivity and Receptor Distribution

Three distinct alpha-1 adrenergic receptor subtypes exist in human tissues:

• Alpha-1A (α1A): Represents approximately 70% of alpha-1 receptors in the human prostate, bladder neck, and prostatic urethra. Mediates dynamic smooth muscle contraction. Selective blockade relaxes the bladder outflow tract with minimal vascular impact.
• Alpha-1B (α1B): Predominates on vascular smooth muscle cells (arterioles and venules). Mediates peripheral vasoconstriction and maintains systemic blood pressure. Blockade causes peripheral vasodilation, orthostatic hypotension, reflex tachycardia, dizziness, and syncope.
• Alpha-1D (α1D): Predominates in the bladder detrusor dome, sacral spinal cord, and nasal mucosa. Modulates detrusor irritative storage symptoms and bladder sensation.

Intraoperative Floppy Iris Syndrome (IFIS)

First characterized by Chang and Campbell in 2005, Intraoperative Floppy Iris Syndrome (IFIS) is a pharmacologically induced surgical complication occurring during phacoemulsification cataract extraction. The syndrome is defined by a classic intraoperative triad:

1. A flaccid, billowing iris stroma that waves in response to normal intraocular fluid currents;
2. Progressive, involuntary intraoperative pupillary constriction (miosis) despite preoperative pharmacological mydriasis;
3. A marked propensity for the iris stroma to prolapse through the corneal or scleral surgical incisions.

Pathophysiology: Alpha-1 antagonism reduces iris dilator muscle tone, particularly with tamsulosin. IFIS can occur with current or previous exposure. Persistent changes in iris function help explain why a short drug-free interval cannot be relied on to eliminate risk; the operative concern is the exposure history, not an assumed safe washout period.

Clinical Management Pearl: Stopping an alpha-blocker before cataract surgery does not reliably eliminate IFIS risk. Inform the ophthalmologist of current and previous exposure; avoid initiating an alpha-blocker immediately before scheduled cataract surgery. The ophthalmologist selects precautions according to operative findings: intracameral epinephrine or phenylephrine, viscoelastic agents, iris retractors or pupil-expansion rings. Mechanical devices are useful options, not mandatory in every exposed patient. Drug interruption should be coordinated with the treating clinicians.

Ejaculatory Dysfunction

Selective α1A blockade inhibits contraction of the vas deferens and seminal vesicles, reducing or abolishing seminal emission. A dry orgasm during tamsulosin or silodosin treatment should not automatically be called retrograde ejaculation. Silodosin has a high reported incidence of ejaculatory dysfunction (~28% in pivotal trials); trial analyses associate this effect with greater symptom and flow improvement. The effect is usually reversible after cessation; libido and erectile function are generally preserved, although ejaculatory changes may be bothersome.

---

2. 5-Alpha-Reductase Inhibitors (5-ARIs)

5-alpha-reductase inhibitors block the intracellular conversion of testosterone into the significantly more potent androgen dihydrotestosterone (DHT) within target tissues.

Isozymes and Comparative Pharmacology

• Type 1 5-alpha-reductase: Expressed primarily in extraprostatic tissues, including liver, skin, and sebaceous glands. Responsible for roughly one-third of circulating DHT.
• Type 2 5-alpha-reductase: Predominates in the prostate stroma and basal epithelial cells, seminal vesicles, and hair follicles. Responsible for the majority of intraprostatic DHT synthesis and androgen-dependent prostatic growth.

Finasteride (5 mg daily): A competitive, selective inhibitor of the Type 2 isozyme. Suppresses intraprostatic DHT by ~85%–90% and serum DHT by ~70%.

Dutasteride (0.5 mg daily): A dual, competitive inhibitor of both Type 1 and Type 2 isozymes. Suppresses intraprostatic DHT by approximately 85%–90% and serum DHT by approximately 95%.

Clinical Efficacy and Progression Prevention

Unlike alpha-blockers, 5-ARIs alter the natural history of benign prostatic hyperplasia. Landmark multi-year randomized clinical trials (PLESS, MTOPS, CombAT) established that 5-ARIs:

• Induce apoptosis in prostatic glandular epithelium, reducing total prostate volume by 18% to 28% after 6 to 12 months of therapy;
• After two to four years, improve Qmax by approximately 1.5–2.0 mL/s and IPSS by 15%–30%;
• In PLESS, finasteride reduced four-year relative risks of AUR by 57% and BPH surgery by 55% versus placebo;
• In MTOPS, the corresponding finasteride reductions were 68% for AUR and 64% for surgery.

Therapeutic Selection: EAU recommends 5-ARIs for men with moderate-to-severe LUTS and increased progression risk, for example a prostate volume >40 mL. PSA can help estimate enlargement and progression risk; an elevated PSA alone is not the indication. Dutasteride also has evidence of benefit with volumes of 30–40 mL. Explain the slow onset and sexual adverse effects.

The PSA Doubling Rule and Cancer Detection

Continuous treatment with finasteride or dutasteride suppresses circulating total serum PSA by approximately 50% after 6 to 12 months of compliance.

• Interpretation Rule: After ≥6 months, double an isolated PSA value for an approximate comparison with untreated reference ranges. Establish a new on-treatment baseline at six months and follow the measured trend. The doubling rule is an estimate, not a measurement of the pretreatment value.
• Oncologic Warning: A confirmed increase from the on-treatment nadir warrants evaluation, including adherence and prostate-cancer risk assessment. It does not diagnose cancer or its grade. MRI and biopsy decisions follow the clinical risk pathway.

Combination Therapy: CombAT & MTOPS Evidence

Long-term CombAT (dutasteride/tamsulosin) and MTOPS (finasteride/doxazosin) results support combination treatment for men with moderate-to-severe LUTS and increased progression risk. Combination improves symptoms and flow more than monotherapy and reduces AUR/surgery compared with alpha-blocker alone. Clinical progression included worsening symptom scores and events such as retention, incontinence, infection or renal impairment. Consider withdrawing the alpha-blocker after 6–9 months in selected responders; men with severe baseline symptoms may benefit from longer combination treatment. Continue the 5-ARI as long-term therapy.

---

3. Muscarinic Receptor Antagonists (Anticholinergics)

Muscarinic receptor antagonists are indicated for storage LUTS, urgency, frequency, and urgency urinary incontinence associated with overactive bladder (OAB) syndrome in men and women.

Receptor Distribution and Detrusor Physiology

Human detrusor smooth muscle expresses both M2 and M3 muscarinic receptors:

• M2 Receptors: Account for approximately 80% of all muscarinic receptors in the bladder. They inhibit sympathetically mediated beta-adrenergic relaxation by inhibiting adenylyl cyclase, indirectly facilitating contraction.
• M3 Receptors: Account for roughly 20% of detrusor receptors, but represent the primary mediator of direct, acetylcholine-induced detrusor smooth muscle contraction during voiding. M3 receptors also control salivary gland secretion, gastrointestinal motility, and pupillary constriction.
• M1 and M2 Central Receptors: Located in the cerebral cortex and hippocampus, where they mediate cholinergic memory consolidation, learning, and executive cognitive functioning.

Agent Selectivity and Blood-Brain Barrier Penetration

• Oxybutynin: Non-selective (M1, M2, M3). Highly lipophilic, neutral tertiary amine that readily crosses the blood-brain barrier. Extensively metabolized by hepatic CYP3A4 to the active metabolite N-desethyloxybutynin, which achieves high salivary gland concentrations and causes severe dry mouth (~60%–70% with oral IR). Carries the highest risk of cognitive decline and hallucinations in elderly patients. Transdermal patch and gel bypass first-pass hepatic metabolism, drastically lowering N-desethyloxybutynin levels and reducing xerostomia.
• Tolterodine: Tertiary amine; non-selective; lower lipophilicity than oxybutynin. Metabolized via hepatic CYP2D6 into active 5-hydroxymethyltolterodine (5-HMT).
• Fesoterodine: A prodrug rapidly hydrolysed by non-specific esterases to active 5-HMT. Activation bypasses CYP2D6, but subsequent 5-HMT clearance involves CYP2D6, CYP3A4 and renal excretion; poor CYP2D6 metabolism can increase exposure.
• Solifenacin: Exhibits moderate selectivity for M3 over M2 receptors.
• Darifenacin: Highly selective for M3 over M1, M2, M4, and M5 receptors (M3 selectivity >9-fold over M1), minimizing central cognitive adverse effects.
• Trospium Chloride: A hydrophilic, synthetic quaternary ammonium compound. Its permanent positive charge and low lipid solubility limit blood-brain barrier penetration. Renal elimination is important, without significant hepatic CYP metabolism. It may be considered when an antimuscarinic is needed in an older patient, with review of renal function, cognition and total anticholinergic burden.

Safety, Adverse Effects, and Contraindications

Common peripheral adverse effects include xerostomia (dry mouth), constipation, blurred vision (cycloplegia), tachycardia, and dyspepsia.

• Urinary Retention Caution: Measure baseline PVR and reassess symptoms and emptying. EAU advises not using antimuscarinic OAB drugs in men with PVR >150 mL; stop and review treatment if voiding worsens.
• Absolute Contraindications: Untreated shallow anterior chamber or narrow-angle (angle-closure) glaucoma (drug-induced mydriasis can precipitate angle closure in a susceptible eye), severe myasthenia gravis, toxic megacolon, and gastric retention.

---

4. Beta-3 Adrenergic Receptor Agonists

Beta-3 agonists represent a non-anticholinergic mechanism for treating OAB storage symptoms.

Mechanism of Action

• Human detrusor smooth muscle expresses β3-adrenergic receptors. During the urine storage/filling phase, endogenous norepinephrine released from lumbar sympathetic postganglionic fibers stimulates β3 receptors.
• Receptor stimulation couples to G-alpha-s proteins, activating adenylyl cyclase and increasing intracellular cyclic adenosine monophosphate (cAMP).
• Elevated cAMP promotes protein kinase A (PKA)-dependent phosphorylation, deactivating myosin light-chain kinase and sequestering intracellular calcium. This relaxes detrusor smooth muscle during filling, increasing bladder capacity and compliance without diminishing voiding detrusor contractility or increasing PVR.

Clinical Agents and Monitoring

• Mirabegron (25 mg, 50 mg once daily): Demonstrated clinical efficacy equivalent to antimuscarinics in reducing urgency episodes and incontinence pads. It avoids anticholinergic burden and causes less dry mouth than antimuscarinics. However, mirabegron can cause dose-dependent increases in blood pressure (mean systolic increase 1–3 mmHg) and pulse rate due to off-target β1/β2 stimulation. It is contraindicated in patients with severe uncontrolled hypertension (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg). Regular blood pressure monitoring is required. Mirabegron is also a moderate inhibitor of CYP2D6 (interacts with metoprolol, flecainide).
• Vibegron (75 mg once daily): Highly selective β3 agonist with negligible activity at β1 or β2 receptors. Does not inhibit hepatic CYP enzymes (no CYP2D6 drug interactions) and demonstrates no clinically significant elevation in blood pressure or heart rate.

---

5. Phosphodiesterase Type 5 (PDE5) Inhibitors for LUTS

• Tadalafil (5 mg once daily): The sole PDE5 inhibitor licensed for male LUTS secondary to BPH, with or without comorbid erectile dysfunction.
• Mechanism: Inhibits PDE5 breakdown of cyclic guanosine monophosphate (cGMP) in smooth muscle cells of the prostate stroma, bladder neck, and pelvic vasculature. Increased intracellular cGMP decreases smooth muscle tone, improves pelvic perfusion/oxygenation, and modulates bladder afferent nerve activity. Tadalafil improves IPSS scores by approximately 2–4 points versus placebo and erectile function (IIEF-5), but does not significantly increase Qmax or alter prostate volume.
• Contraindications: Strictly contraindicated in patients taking organic nitrates (e.g., glyceryl trinitrate, isosorbide mononitrate/dinitrate) or soluble guanylyl cyclase stimulators (riociguat), because concurrent cGMP accumulation causes catastrophic, refractory vasodilation and life-threatening hypotension. Co-administration with non-selective alpha-blockers (doxazosin, terazosin) should be avoided; co-administration with tamsulosin 0.4 mg is acceptable with appropriate blood pressure surveillance.

---

6. Desmopressin for Nocturia

• Mechanism: Desmopressin (1-deamino-8-D-arginine vasopressin, dDAVP) is a synthetic peptide analogue of endogenous arginine vasopressin (antidiuretic hormone, ADH). It acts as a highly selective agonist at V2 vasopressin receptors located on the basolateral membrane of renal collecting duct principal cells. V2 activation stimulates cAMP-dependent phosphorylation and exocytosis of aquaporin-2 water channel vesicles into the apical membrane, dramatically increasing water reabsorption and concentrating urine during sleep.
• Indication: Nocturia secondary to nocturnal polyuria (defined as nocturnal urine production >20%–33% of total 24-hour volume, depending on age).
• Formulation: Orally disintegrating sublingual lyophilisate (MELT) formulation at gender-specific doses: 25 mcg for women and 50 mcg for men taken 1 hour before bedtime. Women are more sensitive to desmopressin, supporting the lower dose.
• Hyponatremia Risk: Dilutional hyponatremia is the most severe, potentially lethal complication of desmopressin, driven by unregulated water retention. It occurs predominantly in patients aged ≥65 years. EAU monitoring: check sodium at baseline, day 3, day 7 and one month, then periodically, with closer monitoring in older or higher-risk patients. Restrict fluids to a minimum from one hour before until eight hours after dosing.
• Contraindications: Hyponatraemia or a history of it, creatinine clearance <50 mL/min, SIADH, polydipsia, and cardiac insufficiency or fluid overload requiring diuretics, including a history of these conditions. Stop and reassess treatment if sodium falls below 135 mmol/L or fluid-retention symptoms develop.

---

Summary of Drug Classes for Lower Urinary Tract Disorders